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Pancreatic cancer is a lethal disease without effective treatments at present. It ranks as s as 4th and 5th in
cancer-related mortality in the western countries and worldwide. Locally advanced pancreatic duct carcinoma
(PDAC) and metastatic PDAC, usually found the metastases over liver, peritoneum, or lung, have been shown to be
with dismal prognosis. Brain metastasis is a rare entity and most cases reported before were found post-mortem.
Intraductal papillary mucinous neoplasms of the pancreas (IPMN) has been deemed as a precursor of PDAC with
very slow progression rate. Here we reported a case diagnosed with IPMN-derived PDAC with brain metastasis.
After surgeries for PDAC and brain metastasis, subsequent chemotherapy and radiotherapy were also given. One
and half year after surgery, this patient is still living with good performance status, which may warrant
individualization of therapeutic strategy for PDAC with only brain metastasis.
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Pancreatic duct adenocarcinoma (PDAC) is a lethal
human malignancies with a very poor prognosis. PDAC
ranks as the eighth and ninth most common cause of
cancer-related mortality worldwide for men and women,
respectively [1]. The overall 5-year survival rate of pa-
tients with PDAC is only 1–4% approximately, which is
possibly contributable to the aggressive characteristics of
PCA [1]. PCA usually presents with early local spread
and metastasis and resistance to traditional radiotherapy
and systemic chemotherapies. At present, radical sur-
gical resection remains the cornerstone of treatment.
For advanced PDAC, the treatment strategy tends to be
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reproduction in any medium, provided the orIntraductal papillary mucinous neoplasms of the pan-
creas (IPMN) has been deemed as a precursor of PDAC
with very slow progression rate. Here we reported a case
diagnosed with IPMN-derived PDAC with brain metas-
tasis. After aggressive surgeries for PDAC and brain me-
tastasis and subsequent chemotherapy and radiotherapy,
this patient is still l living well at the time of writing,
which may encourages an aggressive treatment strategy
against patients with PDAC with brain metastasis.
Case presentation
A 54-year-old male patient with an unexceptional med-
ical history complained of several episodes of right-sided
weakness and tripping in November, 2009. After one
episode of tumbling on January 2, 2010, he was brought
to our emergency department by his family. Data from
blood biochemistry and other blood tests were all within
normal ranges. Due to the presence of neurologic symp-
toms and signs, a computed tomography (CT) scan of
the patient’s brain was performed. The scan revealed a
2.9-cm low-density mass over the left frontal lobe, withLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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edema reaching the corpus callosum, and crossing the
midline (Figure 1A).
A craniotomy was conducted on January 15, in the ex-
pectation of finding a brain abscess or tumor. During
the operation, the cystic lesion was shown to contain
no bacteria; the tumor was then resected subtotally
due to its proximity to the motor area. The final path-
ology report indicated that the tumor was composed
of branching complex papillae and occasional tubules
(Figure 2A), with abundant oncocytic cytoplasm, large
round nuclei with prominent nucleoli, and frequent mi-
toses (Figure 2B). Immunohistochemically, the tumor
cells stained positively for cytokeratin 7, but were nega-
tive for cytokeratin 20, thyroid transcription factor 1
(TTF1), caudal-related homeobox transcription factor 2
(CDX2), and prostate-specific antigen, which indicated
a metastatic rather than a primary brain tumor, which
was unlikely to be derived from lung, gastrointestinal
tract, or lung.
A subsequent CT scan of chest and abdomen showed
a 2.7-cm hypodense lesion in the uncinate process of
the pancreas with pancreatic duct dilatation, suggesting
pancreatic cancer (Figure 1B). Magnetic resonanceFigure 1 Computed tomography (CT) and magnetic resonance (MR) i
brain shows a ring-enhancing lesion (arrow) in the left frontal lobe with pe
hypodense lesion (arrow) in the uncinate process of the pancreas with min
image shows a mildly hyperintense mass (arrow) in the uncinate process o
vein (arrow head). (d) 1D MR cholangiopancreatography image shows dila
dilatation of the biliary tree is noted.cholangiopancreaticography (MRCP) (Figure 1C, D) was
performed, revealing a 3.2-cm mass in the uncinate
process of the pancreas with encasement of the superior
mesenteric vein and pancreatic duct dilatation; the mass
was radiologically staged as T4N0M0, according to the
American Joint Committee on Cancer’s Cancer Staging
Manual, 7th editionA laparotomy was performed on the
patient on February 26, 2010. The cancer was adhesive
to the portal vein and superior mesentery artery, but was
separable from them. The regional lymph nodes were
grossly normal. A pylorus-preserving Whipple operation
was then conducted, after which the patient recovered
well and was discharged 2 weeks later. The resected
pancreas showed a 4.5 × 4 × 2-cm infiltrative gray-white
tu>mor, with some dilated ducts containing polypoid
tumors. Histologically, the solid tumor showed diffusely
infiltrating tubules and branching complex papillae com-
posed of oncocytic cells having mildly pleomorphic
nuclei (Figures 3A and 3B). In contrast, the dilated
ducts contained polypoid tumors composed of oncocytic
cells forming complex arborizing papillae and tubules
(Figures 3C and 3D). Obvious mucin production was
noted throughout the tumors. These tumors were immu-
noreactive with the mucin proteins MUC1 (Figure 3E)maging. (a) Axial contrast-enhanced computed tomography of the
rifocal edema. (b) Axial contrast-enhanced CT of abdomen shows a
imal encasement of the superior mesenteric vein. (c) 1 C T2-weighted
f the pancreas with minimal encasement of the superior mesenteric
tation of the pancreatic duct with abrupt termination (arrow). No
Figure 2 Histological examination of the resected brain tumor. (a) The brain tumor shows complex branching papillary structures with
occasional tubular formation. (b) The tumor cells present large round nuclei with prominent nucleoli and abundant oncocytic cytoplasm. Mitoses
are frequently seen.
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MUC6, and CDX2.
The immunophenotypes of the patient’s metastatic
brain tumor were almost identical to those of the pan-
creatic tumors, except that they showed strong MUC6
staining. Additionally, both brain and pancreatic tu-
mors showed a G12V (GGT!GTT) mutation in codon
12 of exon 1 of the KRAS gene [NCBI ID:3845] (data
not shown). Taken together, these findings suggested a
final diagnosis of oncocytic-type intraductal papillary mu-
cinous neoplasm (IPMN)-derived invasive oncocytic car-
cinoma with brain metastasis [2,3], staged as T3N0M1.
After the operation, the patient received combined
chemotherapy and radiotherapy (CCRT) consisting of ir-
radiation of the whole brain with 3000 cGy, plus a boost of
1500 cGy divided into 5 doses; radiation of the pancreatic
tumor bed with 5040 cGy divided into 28 doses, and
chemotherapy based on cisplatin and 5-fluorouracil (5-FU).
During follow-up, no recurrence or metastasis was noted
in the abdomen or elsewhere, with the exception of residual
brain metastases, which presented with stationary status.
The performance status of this patient remains good at the
time of writing, 20 months after the operation.
Discussion
Oncocytic-type intraductal papillary mucinous neoplasm
(IPMN), first identified by Ohhashi et al. [4] in 1992
and first recognized by the World Health Organization
(WHO) in 1996, is characterized by the presence of
mucin-producing epithelial cells and cystic dilation in
the pancreatic ducts. IPMNs represent more than one-
third of all cystic neoplasms of the pancreas but less
than 1% of all pancreatic tumors [5,6]. The malignancy
potential of IPMNs is low; they are categorized histologi-
cally as low-grade, moderate-grade, high-grade, or in-
vasive ductal carcinomas (IPMN-INV) [2,7]. AlthoughIPMN is believed to progress slowly and to have a better
prognosis after resection than pancreatic duct carcinoma
(PDAC) [8,9], resected IPMNs have been found to in-
clude PDAC in 40% to 60% of cases [2,10-12]. On the
basis of previous reports, the progression time from
IPMN to PDAC varies, ranging from 5 to 20 years
[10,13,14].
IPMN-derived PDACs have been divided into three
distinctive subtypes: colloid carcinoma, oncocytic carcin-
oma, and tubular carcinoma [15]. Some studies have
shown that IPMNs associated with invasive carcinomas
result in better survival rates than conventional PDAC
[16,17]. However, a recent matched-control study con-
ducted by Yopp et al. showed that while IPMNs with in-
vasive colloid carcinoma had a better prognosis than
conventional PDAC [18], IPMNs with invasive tubular
carcinoma had a prognosis comparable to that of con-
ventional PDAC. Mino-Kenudson et al. further demon-
strated that IPMNs with invasive colloid and oncocytic
carcinoma had better survival rates than conventional
PDAC, while IPMNs with invasive tubular carcinoma had
a survival rate similar to that of conventional PDAC [15].
Here, we report a patient diagnosed with invasive
oncocytic carcinoma derived from the oncocytic type of
IPMN combined with sole brain metastasis, initially pre-
senting with neurologic symptoms. As shown in a previ-
ous study, pancreatic cancer metastasizes predominantly
to the liver and peritoneal cavity, as is usually found in
locally advanced PDAC [19]. The incidence of brain me-
tastases from pancreatic cancer is very low, with most
cases being found post-mortem along with metastasis to
places in addition to the brain [20,21]. Olson et al.
reported the first ante-mortem case of PDAC with brain
metastasis [22]. Recently, Marco et al. reported a case
with PDAC staged as T3N1, in which the patient under-
went R0 resection [radical resection ] and subsequent
Figure 3 Histological examination of the resected pancreatic tumor. (a) The pancreatic head tumor shows complex branching papillary
structures and infiltrating tubules. (b) The tumor cells contain mildly pleomorphic nuclei and oncocytic cytoplasm. (c) The dilated duct displays a
polypoid tumor with complex arborizing papillary and tubular structures. (d) The tumor cells exhibit mildly pleomorphic nuclei and oncocytic
cytoplasm. (e) Tumor cells are immunohistochemically positive for mucin protein, MUC1. (f) Mucin protein MUC5AC is positive for tumor cells
under immunohistochemical stain.
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sis occurred and gemcitabine-based chemotherapy was
given [23]. To our knowledge, this is the first case of
IPMN-derived PDAC with sole brain metastasis. Gener-
ally, the treatment for locally advanced PDAC or PDAC
with metastasis is palliative, and the median survival
time is within 10 months under current standard treat-
ments (mostly gemcitamine-based chemotherapy) [24].
To the contrary, Vazquez et al. recently reported that
patients with adrenal metastasis from pancreatic cancer
seemed to be benefited by resection of metastatic and
origin sites [25]. Patients with pancreatic cancer with
one-sided liver metastasis used to undergo the Whipple
operation and hepatectomy; however, no obvious im-
provement in survival has been reported. Some studies
have shown that chemoradiotherapy could be morebeneficial to patients than radiotherapy alone [26,27].
Used as a single agent to treat advanced PDAC, 5-FU
has been studied extensively since the 1950s, with a
range of objective response rates, varying from 0% to
67% [28]: 5-FU has also been combined with other
agents, such as doxorubicin, cisplatin, cyclophospha-
mide, methotrexate, vincristine, and mitomycin, to treat
advanced PADC. However, no significant survival bene-
fit has been observed [29].
In the present case, our patient initially presented with
neurologic symptoms and so was treated initially on the
assumption that he was suffering from a brain abscess.
After serial examinations, PDAC with brain metastasis
was highly suspected. Although radical therapy for this
situation was not feasible, due to the previous subtotal
excision of the metastatic brain lesion and the fact that no
Chiang et al. World Journal of Surgical Oncology 2012, 10:138 Page 5 of 6
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after discussion with his family, the Whipple operation
was conducted and his final local stage was, surprisingly,
T3N0. Subsequent radiotherapy and a combination of
cisplatin and 5-FU chemotherapy were given and, at
present, this patient is still alive with good performance
status 2 years after surgery.
Conclusions
On the basis of this case, we suggest that an aggressive
therapeutic strategy may benefit some IPMN-derived
PDAC patients presenting solely with brain metastasis.
IPMN-derived PDAC with sole brain metastasis war-
rants individual treatment.
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